Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

被引：3
|
作者：
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
80
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    Van der Spek, Ellen
    Bilgin, Yavuz M.
    Kentos, Alain
    Sohne, Maaike
    van Kampen, Roel J. W.
    Ludwig, Inge
    Thielen, Noortje
    Durdu-Rayman, Nazik
    de Graauw, Nicole C. H. P.
    van de Donk, Niels W. C. J.
    de Waal, Esther G. M.
    Vekemans, Marie-Christiane
    Timmers, Gert Jan
    van Der Klift, Marjolein
    Soechit, Savita
    Geerts, Paul A. F.
    Silbermann, Matthijs H.
    Oosterveld, Margriet
    Nijhof, Inger S.
    Sonneveld, Pieter
    Klein, Saskia K.
    Levin, Mark-David
    Zweegman, Sonja
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) : 2758 - +
  • [2] Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
    Groen, Kaz
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    de Heer, Koen
    van Kampen, Roel J. W.
    Leys, Rineke B. L.
    Thielen, Noortje
    Westerman, Matthijs
    Wu, Ka-Lung
    Ludwig, Inge
    Issa, Djamila E.
    Velders, Gerjo A.
    Vekemans, Marie-Christiane
    Timmers, Gert-Jan
    de Boer, Fransien
    Tick, Lidwine W.
    Verbrugge, Annelies
    Buitenhuis, Danny
    Cunha, Sonia M.
    van der Spek, Ellen
    de Waal, Esther G. M.
    Sohne, Maaike
    Sonneveld, Pieter
    Nijhof, Inger S.
    Klein, Saskia K.
    van der Donk, Niels W. C. J.
    Levin, Mark-David
    Ypma, Paula F.
    Zweegman, Sonja
    ECLINICALMEDICINE, 2023, 63
  • [3] Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    Levin, Mark-David
    Thielen, Noortje
    Klein, Saskia K.
    Ludwig, Inge
    Westerman, Matthijs
    Ypma, Paula F.
    Bilgin, Yavuz
    Sohne, Maaike
    de Waal, Esther
    van de Donk, Niels W. C. J.
    Sonneveld, Pieter
    Zweegman, Sonja
    BLOOD, 2018, 132
  • [4] Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study
    Stege, Claudia A. M.
    Nasserinejad, Kazem
    van der Spek, Ellen
    Van Kampen, Roel J. W.
    Sohne, Maaike
    Thielen, Noortje
    Bilgin, Yavuz
    De Waal, Esther G. M.
    Ludwig, Inge
    Leijs, Maria B. L.
    Kentos, Alain
    Timmers, Gert Jan
    de Heer, Koen
    Westerman, Matthijs
    Vekemans, Marie Christiane
    Durdu-Rayman, Nazik
    van der Burg-de Graauw, Nicole C. H. P.
    Van de Donk, Niels W. C. J.
    Sonneveld, Pieter
    Klein, Saskia K.
    Levin, Mark-David
    Zweegman, Sonja
    BLOOD, 2019, 134
  • [5] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Kapoor, Prashant
    Gertz, Morie A.
    Laplant, Betsy
    Malave, Gabriella C.
    Wolfe, Eric
    Muchtar, Eli
    Siddiqui, Mustaqeem A.
    Gonsalves, Wilson I.
    Emanuel, Angie R.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Buadi, Francis K.
    Hayman, Suzanne R.
    Leung, Nelson
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Dispenzieri, Angela
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [6] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    BLOOD, 2018, 132
  • [7] Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).
    Lacy, Martha
    Bergsagel, P. Leif
    LaPlant, Betsy
    Halvorson, Alese
    Buadi, Francis
    Leung, Nelson
    Go, Ronald S.
    Dingli, David
    Kapoor, Prashant
    Gertz, Morie A.
    Lin, Yi
    Dispenzieri, Angela
    Hwa, Yi Lisa
    Fonder, Amie
    Fonseca, Rafael
    Hayman, Suzanne R.
    Stewart, A. Keith
    Mikhael, Joseph
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
    O'Donnell, Elizabeth K.
    Suman, Vera Jean
    Geyer, Susan M.
    Nadeem, Omar
    Dinner, Shira
    Yee, Andrew J.
    Laubach, Jacob P.
    Mo, Clifton C.
    Tuchman, Sascha A.
    Donadio, Kristen
    Sinclair, Sarah
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [9] Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Chung, Joo-Seop
    Joo, Young-Don
    Lee, Jae-Hoon
    Lee, Jung-Lim
    Ahn, Jae-Sook
    Moon, Joon-Ho
    Shin, Ho-Jin
    Choi, Young-Jin
    Lee, Won-Sik
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 62 - 67
  • [10] Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
    Suzuki, Kenshi
    Shinagawa, Atsushi
    Uchida, Toshiki
    Taniwaki, Masafumi
    Hirata, Hirokazu
    Ishizawa, Kenichi
    Matsue, Kosei
    Ogawa, Yoshiaki
    Shimizu, Takayuki
    Otsuka, Maki
    Matsumoto, Morio
    Iida, Shinsuke
    Terui, Yasuhito
    Matsumura, Itaru
    Ikeda, Takashi
    Takezako, Naoki
    Ogaki, Yumi
    Midorikawa, Shuichi
    Houck, Vanessa
    Ervin-Haynes, Annette
    Chou, Takaaki
    CANCER SCIENCE, 2016, 107 (05) : 653 - 658
12345